SAN DIEGO, March 10, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius Therapeutics, will provide a corporate presentation on Tuesday, March 15 at 10:30 a.m. at BIO-Europe Spring 2011. The presentation will take place in Milan, Italy at the Milano Convention Centre in Level 1, Room Yellow 3.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit .
CONTACT: Public Relations Contact:         Jason Spark at Canale Communications, Inc.         619-849-6005                  Investor Relations Contact:         Stefan Loren at Westwicke Partners, LLC         443-213-0507